OBJECTIVE: The objective of this study is to outline the evidence regarding the surgical management of esophageal cancer and provide a single institutional outline regarding its implementation. BACKGROUND: Esophageal cancer is a major cause of cancer-related morbidity and mortality worldwide. Surgery continues to play an important role in its management and offers the best chance for cure in localized and locally advanced disease. However, considerable controversy exists regarding the optimum treatment strategy in this patient population. Furthermore, despite advances in operative and perioperative care and the advent of minimally invasive approaches, the majority of patients succumb to distant metastases after curative intent resection. This failure highlights the importance of multimodal, stage-directed therapy in the management of patients with newly diagnosed esophageal tumors. METHODS: Herein, we provide a comprehensive, evidence-based review of the diagnostic workup and locoregional and systemic treatment options available to esophageal cancer patients. The evidence supporting perioperative chemotherapy versus chemoradiotherapy is outlined and discussed. In addition, we highlight our institutional approach to the diagnostic evaluation, operative selection strategy, and perioperative treatment regimen selection based on the stage of presentation. Finally, we discuss the role of enhanced recovery in the postoperative management of this complex group of patients. CONCLUSIONS: Esophageal cancer remains a devastating disease with high mortality. Favorable outcomes mandate a multimodal, stage-directed treatment approach.
OBJECTIVE: The objective of this study is to outline the evidence regarding the surgical management of esophageal cancer and provide a single institutional outline regarding its implementation. BACKGROUND:Esophageal cancer is a major cause of cancer-related morbidity and mortality worldwide. Surgery continues to play an important role in its management and offers the best chance for cure in localized and locally advanced disease. However, considerable controversy exists regarding the optimum treatment strategy in this patient population. Furthermore, despite advances in operative and perioperative care and the advent of minimally invasive approaches, the majority of patients succumb to distant metastases after curative intent resection. This failure highlights the importance of multimodal, stage-directed therapy in the management of patients with newly diagnosed esophageal tumors. METHODS: Herein, we provide a comprehensive, evidence-based review of the diagnostic workup and locoregional and systemic treatment options available to esophageal cancerpatients. The evidence supporting perioperative chemotherapy versus chemoradiotherapy is outlined and discussed. In addition, we highlight our institutional approach to the diagnostic evaluation, operative selection strategy, and perioperative treatment regimen selection based on the stage of presentation. Finally, we discuss the role of enhanced recovery in the postoperative management of this complex group of patients. CONCLUSIONS:Esophageal cancer remains a devastating disease with high mortality. Favorable outcomes mandate a multimodal, stage-directed treatment approach.
Authors: Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta Journal: Lancet Date: 2012-05-01 Impact factor: 79.321
Authors: Luca M Saadeh; Annelijn E Slaman; Eleonora Pinto; Suzanne S Gisbertz; Francesco Cavallin; Egle Jezerskyte; Rita Alfieri; Loes Noteboom; Maria Cristina Bellissimo; Matteo Cagol; Giovanni Pirozzolo; Carlo Castoro; Marco Scarpa; Mark I van Berge Henegouwen Journal: J Thorac Dis Date: 2018-08 Impact factor: 2.895
Authors: Philippe Bouchard; Juan-Carlos Molina; Jonathan Cools-Lartigue; Jonathan Spicer; Carmen L Mueller; Lorenzo E Ferri Journal: J Gastrointest Surg Date: 2019-01-31 Impact factor: 3.452
Authors: J C Molina; A Al-Hinai; A Gosseling-Tardif; P Bouchard; J Spicer; D Mulder; C L Mueller; L E Ferri Journal: J Gastrointest Surg Date: 2018-04-16 Impact factor: 3.452
Authors: Michele Valmasoni; Elisa Sefora Pierobon; Alberto Ruol; Carlo Alberto De Pasqual; Gianpietro Zanchettin; Lucia Moletta; Renato Salvador; Mario Costantini; Stefano Merigliano Journal: PLoS One Date: 2016-04-18 Impact factor: 3.240